Fred Alger Management LLC Lowers Stock Holdings in Insulet Corporation $PODD

Key Points

• Fred Alger Management LLC decreased its holdings in Insulet Corporation by 32.5%, selling 6,153 shares in the first quarter, leaving them with 12,764 shares valued at approximately $3.35 million.
• Several hedge funds have adjusted their stakes in Insulet, with Larson Financial Group increasing its investment by 426.3%, adding 81 shares worth $26,000.
• Insulet reported a 35% increase in revenue year-over-year, achieving $649.1 million for the quarter and surpassing analyst expectations.

Fred Alger Management LLC cut its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 32.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,764 shares of the medical instruments supplier's stock after selling 6,153 shares during the period. Fred Alger Management LLC's holdings in Insulet were worth $3,352,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock valued at $2,276,553,000 after purchasing an additional 178,976 shares during the last quarter. American Century Companies Inc. grew its stake in Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock valued at $302,686,000 after purchasing an additional 297,734 shares during the last quarter. Groupama Asset Managment lifted its stake in Insulet by 0.4% during the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock valued at $276,728,000 after acquiring an additional 3,759 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Insulet by 4.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock valued at $177,096,000 after acquiring an additional 27,408 shares during the period. Finally, GAMMA Investing LLC lifted its stake in Insulet by 27,298.6% during the 1st quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock valued at $1,744,100,000 after acquiring an additional 661,717 shares during the period.

Analyst Upgrades and Downgrades

PODD has been the subject of several research reports. Morgan Stanley restated an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Barclays boosted their target price on shares of Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Jefferies Financial Group reiterated a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Finally, The Goldman Sachs Group initiated coverage on shares of Insulet in a research note on Friday, May 30th. They issued a "buy" rating and a $380.00 target price for the company. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $335.12.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Prem Singh sold 687 shares of Insulet stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares of the company's stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Insulet Trading Up 1.1%

Insulet stock traded up $3.84 during midday trading on Friday, hitting $341.78. 472,873 shares of the stock were exchanged, compared to its average volume of 530,837. Insulet Corporation has a fifty-two week low of $225.37 and a fifty-two week high of $353.50. The stock has a market capitalization of $24.06 billion, a price-to-earnings ratio of 103.88, a PEG ratio of 2.81 and a beta of 1.36. The stock's 50-day simple moving average is $311.59 and its 200 day simple moving average is $291.99. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. During the same period last year, the business earned $0.55 earnings per share. The business's revenue for the quarter was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.